Gastroenterologyclinical trialCrohn’s disease
Evaluating Dose Intensification Strategies for Ustekinumab in Crohn’s Disease: Insights from the REScUE Trial
By MedXY|Jul 13, 2026
The REScUE study compared two ustekinumab dosing intensification regimens after secondary loss of response in Crohn’s disease, finding no superiority of more frequent dosing regarding steroid-free remission at 48 weeks.